Jilin Aodong Pharmaceutical Group Co., Ltd. Jilin Aodong Pharmaceutical Group Co., Ltd.

Jilin Aodong Pharmaceutical Group Co., Ltd.

000623

株式のランク #4845
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
株価
$2.55
最終同期: 2026-10-21
時価総額
$3.05B
変化(1日)
3.33%
変化(1年)
-10.66%
国
CN
取引 Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)

カテゴリー

Healthcare
Jilin Aodong Pharmaceutical Group Co., Ltd.(000623)の収益
Jun 2026 時点の収益 TTM: $324.58M
Jilin Aodong Pharmaceutical Group Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は $324.58M です。2023 年には $487.26M の収益があり、これは 2022 年の $415.81M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Jilin Aodong Pharmaceutical Group Co., Ltd. の収益履歴(2000 ~ 2026)
各年末の収益
年 収益 変化
2026 (TTM) $324.58M -9.25%
2024 $357.66M -26.60%
2023 $487.26M 17.18%
2022 $415.81M 14.72%
2021 $362.46M 5.16%
2020 $344.67M -22.29%
2019 $443.52M -8.22%
2018 $483.25M 5.62%
2017 $457.53M 16.07%
2016 $394.17M 9.63%
2015 $359.54M -0.59%
2014 $361.66M 12.10%
2013 $322.61M 39.17%
2012 $231.80M 27.60%
2011 $181.66M 7.70%
2010 $168.67M 12.29%
2009 $150.21M 10.47%
2008 $135.97M 17.47%
2007 $115.75M 17.31%
2006 $98.67M 3.79%
2005 $95.06M -4.15%
2004 $99.18M 21.83%
2003 $81.41M 17.43%
2002 $69.33M 28.70%
2001 $53.87M 41.79%
2000 $37.99M 0.00%